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Abstract
Mantle cell lymphoma (MCL) is a rare and aggressive type of B-cell non-Hodgkin’s lymphoma. Patients become
progressively refractory to conventional chemotherapy, and their prognosis is poor. However, a 38% remission rate
has been recently reported in refractory MCL treated with temsirolimus, a mTOR inhibitor.
Here we had the opportunity to study a case of refractory MCL who had tumor regression two months after tem-
sirolimus treatment, and a progression-free survival of 10 months. In this case, lymph node biopsies were per-
formed before and six months after temsirolimus therapy. Comparison of the two biopsies showed that
temsirolimus inhibited tumor cell proliferation through cell cycle arrest, but did not induce any change in the
number of apoptotic tumor cells. Apart from this cytostatic effect, temsirolimus had an antiangiogenic effect with
decrease of tumor microvessel density and of VEGF expression. Moreover, numerous patchy, well-limited fibrotic
areas, compatible with post-necrotic tissue repair, were found after 6-month temsirolimus therapy. Thus, temsiroli-
mus reduced tumor burden through associated cytostatic and anti-angiogenic effects.
This dual effect of temsirolimus on tumor tissue could contribute to its recently reported efficiency in refractory
MCL resistant to conventional chemotherapy.
Background
Mantle cell lymphoma (MCL) is an aggressive B-cell
non-Hodgkin’s lymphoma (NHL), representing about
6% of NHL cases. T(11;14)(q13;q32) chromosomal
translocation, one of the most important cytogenetic
abnormalities of MCL, juxtaposes genes of cyclin D1
and of immunoglobulin heavy chain, inducing cyclin D1
over-expression and cell cycle deregulation [1]. Thus,
cyclin D1 over-expression and/or the t(11;14)(q13;q32)
translocation are hallmarks of MCL, included in current
WHO guidelines for MCL diagnosis [2]. MCL patients
are usually diagnosed at an advanced stage (III or IV).
They become progressively refractory to conventional
chemotherapy, and have a poor overall survival [3].
Therefore, alternative therapeutic strategies are actively
studied.
The mammalian Target Of Rapamycin (mTOR) is a
serine/threonine protein kinase. It plays an important
role in cell growth, protein synthesis, and cell-cycle pro-
gression [4]. Since mTOR pathway is constitutively acti-
vated in MCL, it could be a potent therapeutic target
for this disease [5]. Recent clinical trials showed that
temsirolimus (Wyeth Pharmaceutical, Philadelphia, PA),
a mTOR inhibitor, induced a 38% response rate and a
prolonged progression-free survival (PFS) of 3.4-6.9
months in refractory MCL patients [6,7]. We studied
here a refractory MCL patient, who had tumor regres-
sion under temsirolimus treatment.
Case Presentation
A 53-year-old male with generalized lymphadenopathy
and fatigue, was diagnosed as MCL on inguinal lymph
node biopsy. After 10 cycles of CHOP and 2 cycles of
E-CHOP, lymph nodes bulged. Disease was still progres-
sing after 2 cycles of R-ICE. Therefore, R-ICE was
stopped. The patient was recruited in phase III study of
temsirolimus (number: 3066K1-305-WW) on August
2006 but was randomized in investigator’s choice group.
According to the protocol, fludarabine 25 mg/m2 was
infused daily for 5 days, and it was repeated every
28 days. After 8 cycles, fludarabine had to be stopped
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because of severe bone marrow inhibition on March
2007. One year later, enlarged iliac lymph-node com-
pressed ureter, causing renal dysfunction with elevated
blood creatinine. To confirm the diagnosis of recur-
rence, a biopsy of enlarged right cervical lymph node
was performed and the place was noted on CT scan.
After confirmation of the MCL recurrence, the patient
was permitted to enter the temsirolimus treatment
group on March 2008. He received temsirolimus
175 mg/week for 3 weeks, followed by weekly doses of
75 mg. Circulation blood count was monitored weekly,
CT scan and serum chemistry every other month. Tem-
sirolimus was suspended, when absolute neutrophil
count <1000/μl, or hemoglobin <8 g/dl, or platelet
<50000/μl. According to the response criteria for non-
Hodgkin’s lymphoma[8] we use in our hospital, six of
the largest dominant nodes or nodal masses were mea-
sured. The sum of dimensions of these six nodal masses
was recorded before temsirolimus as well as every other
month under temsirolimus treatment. Other lesions
were recorded but not measured. After 2 months of
temsirolimus treatment, a 33% regression of the sum of
dimensions was observed by CT scan (Figure 1). Mean-
while, renal function recovered and blood creatinine
returned to normal level. However, lymph nodes enlar-
gement was still present on CT scan after 6 months of
temsirolimus. To assess the extent of the therapeutic
effect, and to detect a possible early recurrence, a sec-
ond biopsy of the same right cervical lymph node was
performed but in a different direction. Informed consent
was provided according to the Declaration of Helsinki.
Disease remained stable until January 2009 when CT
scan showed a cervical lymph node behind the right
jugular vein bulged. Temsirolimus was then stopped. No
further biopsy was taken. Patient then received arsenic
combined with thalidomide and chlorambucil treatment.
On March 2009, all lymph nodes enlarged, and disease
still progressed after 3 cycles of bortezomib. The patient
finally died of severe bone marrow inhibition and
pulmonary infection after hyperCVAD treatment on
October 2009.
During temsirolimus treatment, leukopenia and
thrombocytopenia occasionally occurred, and disap-
peared after one week of treatment suspension. No sign
of thrombosis was observed.
Cyclin D1, the hallmark of MCL, is the down stream
target of mTOR. Its expression was assessed by immu-
nohistochemical staining (Dako; Glostrup, Denmark;
dilution 1:100) on the two successive biopsies. Tumor
cell proliferation was assessed by Ki67 (Dako; dilution
1:100), apoptosis by cleaved caspase-3 (Cell signaling;
MA, USA; dilution 1:50), microvessel density (MVD) by
CD31 (Dako; dilution 1:50), and angiogenesis cytokine
expression by VEGF-A (R&D system; MN, USA; dilu-
tion 1:200). Irrelevant isotypic antibodies and absence of
primary antibodies were used as controls. Immunos-
tained cells were counted on 5 different microscopic
fields at ×400 magnification, out of fibrotic and necrotic
Figure 1 Computed tomography images of MCL. Areas of major lesions (surrounded by white broken lines) significantly regressed after two
months of temsirolimus treatment.
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areas, the count including a minimum of 1000 cells.
Fibrotic areas were randomized photographed at ×200
magnification for five fields and analysed with Cell Soft-
ware (Olympus, Tokyo). The ratio between fibrotic areas
and tumor areas gave the relative fibrotic area. Differ-
ences between analyses before and after temsirolimus
were assessed with Wilcoxon signed-rank test. Two-
sided P < 0.05 was considered to be significant.
Comparison between the 2 biopsies, before and after
temsirolimus, showed a significant decrease of cyclin D1
(P < 0.01), and Ki67 (P < 0.01). But there was no change
in apoptotic cell counts (P = 0.15). VEGF-A expression
Figure 2 Immunohistostainings and histological analysis of the lymph node biopsies before and six months after temsirolimus.
Quantitative studies showed a significant decrease of cyclin D1, cell proliferation, microvessel density and VEGF-A expression as well as a significant
increase in fibrosis after six months of temsirolimus. Cleaved caspase-3 positive cell counts remained unchanged. Bar, 50 μm. * P < 0.05, ** P < 0.01
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(P <0.05) and microvessel density (P < 0.05) were also
significantly decreased after temsirolimus therapy.
Numerous patchy, well-limited fibrotic areas were
observed within the tumor. Relative fibrotic area signifi-
cantly increased after temsirolimus (P < 0.05) (Figure 2).
Discussion and conclusion
The use of m-TOR inhibitor in MCL is an emerging
therapy [7], but its in vivo anti-tumor mechanism is not
yet fully explained. In this refractory MCL case, temsiro-
limus was able to induce tumor regression as well as a
progression-free survival of 10 months. Tissue analyses
before and after temsirolimus showed the direct cyto-
static effect of this mTOR inhibitor through cell cycle
arrest, as demonstrated by down-regulation of cyclin D1
and Ki67 in lymphoma cells, and the absence of apopto-
tic change. This cytostatic effect observed on human
biopsies is in agreement with experimental results
reported in temsirolimus-treated breast and acute leuke-
mia cell lines [9,10]. However, temsirolimus significantly
reduced tumor burden in our refractory MCL case, an
effect difficult to link only to its cytostatic properties.
Further assessment of its efficiency on lymphoma tissue
showed that the tumor microvessel density and the
VEGF-A expression were both significantly reduced
after treatment. On the same biopsies, we also found
patchy, well-limited fibrotic areas, compatible with post-
necrotic tissue repair [11]. Along this line, tumor infarct
and necrosis linked to tumor microvessel thrombi have
been reported in xenografted pancreas and colon cancer
treated by mTOR inhibitor [12]. Reduction of microves-
sel density and of VEGF-A expression were also found
in another series of xenografted breast cancers [10].
Temsirolimus could thus reduce tumor burden through
a direct cytostatic effect on the tumor cells, but also
through an associated effect on tumor angiogenesis.
This dual effect of temsirolimus on tumor tissue could
contribute to its recently reported efficiency in refrac-
tory MCL resistant to conventional cytotoxic drugs. On
the long term, this supports the evaluation of anti-
angiogenic drugs in refractory MCL.
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